Arboretum Ventures

Arboretum Ventures is a Michigan-based venture capital firm. It specializes in seed-stage, early-stage, mid-stage investments, and growth capital. The company seeks to invest in healthcare sector with a focus on services, medical devices, diagnostics; healthcare information technology, therapeutics, technology based healthcare services, and life science tools. The firm invests throughout the United States with a focus on Midwest and Michigan. It seeks to invest in companies with equity investment between $5 million and $15 million. Arboretum Ventures Jan Garfinkle in 2002 and is headquartered in Michigan.

Cheryl Brown

Financial Analyst

Sarah Jameson

Senior Associate

Marshall, Marcy L.

CFO

Timothy Petersen

Founder and Managing Partner

Nicole Walker

Managing Partner

87 past transactions

Enumera Molecular

Series A in 2022
Enumera Molecular is a life science tools company headquartered in Ann Arbor, MI, developing a scalable biomolecule assessment platform enabling lower-cost, rapid clinical liquid biopsy tests. It helps in transforming the field of clinical molecular testing into a simpler, more actionable tool for physicians to benefit patient care.

Koya Medical

Series B in 2022
Koya Medical is a transformative healthcare company developing breakthrough treatments for lymphedema and venous diseases to increase movement, mobility, and personalized care that is unavailable with traditional compression therapy.

ViaLase

Series A in 2021
ViaLase develops an image-guided femtosecond laser surgical system for the treatment of glaucoma. The company's system focuses on the development of micron-resolution OCT image-guided femtosecond laser technology to create micron-sized customized drainage channels through the trabecular meshwork that connects the anterior chamber to the Schlemm's canal without surgically opening or penetrating the eye, enabling medical professionals to improve glaucoma management with its efficient non-invasive treatment. ViaLase was incorporated in 2019 and is headquartered in Corona Del Mar, California.

Convergent Dental

Series C in 2021
Convergent Dental is a privately-owned dental equipment and technology company developing a computer-aided dental preparation system designed to offer a comfortable patient experience during dental surgeries. It is a carbon-dioxide laser for both hard and soft tissue indications that cuts quietly, finely, and faster than other laser-based systems in dentistry using patented technologies and computer system controls.

Allay Therapeutics

Series C in 2021
Allay is pioneering a new category of ultra-sustained pain therapeutics to transform post-surgical pain management and recuperation for patients and physicians. Allay’s proprietary technology platform combines validated non-opioid analgesics and biopolymers to create dissolvable therapeutics to deliver pain relief within a targeted site over weeks—an order of magnitude greater than the longest-lasting pain treatments currently available. The company’s lead investigational product candidate, ATX101, is currently being evaluated in a Phase 2 clinical study in TKA surgeries. Allay unites a dynamic, global team of entrepreneurs, scientists, clinicians and innovators in the San Francisco Bay Area and Singapore.

Francis Medical

Series B in 2021
Francis Medical is a medical technology company developing therapeutic solutions to treat prostate, kidney, and bladder cancer. Francis Medical is developing a device for treating prostate cancer, the second most common cancer in American men, using a new platform to treat endourological cancers, water vapor technology. The thermal energy stored in sterile water vapor is used to treat cancerous tissue via a simple transurethral procedure, potentially minimizing life-altering side effects.

RareCyte

Series G in 2021
RareCyte is a life science research and diagnostic development company focused on characterizing and isolating rare cells in the blood. RareCyte is dedicated to bringing its innovative technology to the Life Sciences research, drug development, and diagnostic markets providing new tools to answer difficult questions related to cancer and cardiovascular disease. RareCyte's AccuCyte system is an open platform for the unbiased discovery and isolation of circulating tumor cells (CTCs) and circulating endothelial cells (CECs) from whole blood.

Strata Oncology

Series C in 2021
Strata Oncology is a precision oncology company dedicated to transforming cancer care by expanding patient access to precision medicine clinical trials and accelerating drug approval. Strata's national precision oncology platform serves the needs of patients, providers and drug developers by providing a link from patient screening to streamlined enrollment in mutation-matched clinical trials. Follow us on Twitter @StrataOncology.

Navv Systems

Seed Round in 2021
Navv Systems provides healthcare-focused indoor location technology with the NavvTrack platform. Integrated with Apple Maps, NavvTrack empowers hospitals with high-resolution indoor maps and tools to easily locate and manage staff, equipment, and resources. Developed at Henry Ford Innovations in Detroit, Michigan, NavvTrack is deployed in multiple U.S. hospitals, where it streamlines enterprise device management, helps coordinate team workflows and reduces operational costs.

Flosonics

Venture Round in 2021
Flosonics is a medical device company that focuses on developing non-invasive sensors to improve the management of critically ill patients. Flosonics's flagship smart-bandage product, the FloPatch, addresses unmet clinical needs of critically ill patients and the physicians, nurses, and paramedics who care for them in the ambulance, emergency department, operating room, and intensive care unit.

EQRx

Series B in 2021
EQRx operates as a biotechnology company, focused on re-engineering the process from drug discovery to patient delivery with the goal of offering a market-based solution for the rising cost of medicines. By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the company seeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before. The company was founded in 2019 and is based in Cambridge, Massachusetts, United States.

Koya Medical

Venture Round in 2020
Koya Medical is a transformative healthcare company developing breakthrough treatments for lymphedema and venous diseases to increase movement, mobility, and personalized care that is unavailable with traditional compression therapy.

Jumpcode Genomics

Funding Round in 2020
JUMPCODE's CRISPR-mediated rRNA depletion kits remove nucleic acids from sequencing workflows to improve sensitivity and performance. CRISPRclean is a proprietary technology that utilizes the CRISPR/CAS system to cut through the noise by removing unwanted nucleic acid molecules from sequencing libraries while preserving the representational integrity of the non-targeted sequences. Keith Brown founded the company in Carlsbad, California in 2016.

Cardiac Dimensions

Series C in 2020
Cardiac Dimensions, Inc. is a medical device company developing novel interventional tools for the treatment of heart failure and the related condition of mitral valve regurgitation. Our product, the Carillon® Mitral Contour System®, is a groundbreaking, non-surgical device developed to treat functional mitral valve regurgitation. Our system uses a catheter based approach to reshape the mitral valve and reduce mitral regurgitation.

Health Scholars

Series B in 2020
Health Scholars is a developer of medical simulation training software intended to provide clinical education and training. The company's platform is easy to use and scalable across a health system and effectively manages, delivers and includes interactive training content including the only commercially available as well as clinical VR simulation, enabling users to get cost-effective and richer content experience.

EQRx

Series A in 2020
EQRx operates as a biotechnology company, focused on re-engineering the process from drug discovery to patient delivery with the goal of offering a market-based solution for the rising cost of medicines. By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the company seeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before. The company was founded in 2019 and is based in Cambridge, Massachusetts, United States.

Fifth Eye

Series A in 2019
Fifth Eye develops a medical device software that provides a view of a patient’s evolving hemodynamic trajectory. It enables proactive patient care to improve outcomes, avoid adverse events, shorten lengths of stay, and reduce costs.

Lucina

Seed Round in 2019
Lucina Health is a data-driven, enterprise SaaS company that delivers the leading women’s maternity analytics platform to innovative health plans, Medicaid providers and public entities. Lucina Health identifies women at-risk of preterm birth, usually within the first trimester, with personalized health improvement resources, making it easy for care managers to complete actions that optimize the health and well-being of women to improve birth outcomes and to create healthier communities over time.

Pear Therapeutics

Series C in 2019
Pear Therapeutics is a provider of a software-based digital therapeutics platform designed to treat disease and enhance the efficacy of pharmaceuticals. The company's platform combines novel digital interventions with drugs to enhance efficacy well beyond anything that is commercially available or in clinical development, enabling clients to get better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective services for payors.

SonarMD

Series A in 2018
SonarMD offers a care coordination programme proven to keep patients with gut health conditions healthier and out of the hospital. It is a care coordination solution for chronic diseases. For inquiries, email, telephone numbers, and physical addresses are available on their website.

Francis Medical

Series A in 2018
Francis Medical is a medical technology company developing therapeutic solutions to treat prostate, kidney, and bladder cancer. Francis Medical is developing a device for treating prostate cancer, the second most common cancer in American men, using a new platform to treat endourological cancers, water vapor technology. The thermal energy stored in sterile water vapor is used to treat cancerous tissue via a simple transurethral procedure, potentially minimizing life-altering side effects.

Strata Oncology

Series B in 2018
Strata Oncology is a precision oncology company dedicated to transforming cancer care by expanding patient access to precision medicine clinical trials and accelerating drug approval. Strata's national precision oncology platform serves the needs of patients, providers and drug developers by providing a link from patient screening to streamlined enrollment in mutation-matched clinical trials. Follow us on Twitter @StrataOncology.

Cardiac Dimensions

Series B in 2018
Cardiac Dimensions, Inc. is a medical device company developing novel interventional tools for the treatment of heart failure and the related condition of mitral valve regurgitation. Our product, the Carillon® Mitral Contour System®, is a groundbreaking, non-surgical device developed to treat functional mitral valve regurgitation. Our system uses a catheter based approach to reshape the mitral valve and reduce mitral regurgitation.

BioIQ

Venture Round in 2018
BioIQ also known as Jentryx is a health improvement technology company that has implemented the industry’s first integrated, customizable and measurable approach to optimizing investments in corporate health and wellness programs. The company’s unique health screening platform, ecosystem of health improvement tools, and proven methodology for obtaining quantifiable wellness insights are serving beneficiaries across the United States. BioIQ works with some of the largest employers and health companies in the nation and has launched over 3,000 successful health improvement programs since its inception in 2005.

Pear Therapeutics

Series B in 2018
Pear Therapeutics is a provider of a software-based digital therapeutics platform designed to treat disease and enhance the efficacy of pharmaceuticals. The company's platform combines novel digital interventions with drugs to enhance efficacy well beyond anything that is commercially available or in clinical development, enabling clients to get better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective services for payors.

Swift Biosciences

Series D in 2017
Swift Biosciences, Inc. develops molecular biology reagents for research and diagnostic applications. Swift Biosciences, Inc. is based in Ann Arbor, Michigan.

Aira

Series B in 2017
Called a Godsend by The New York Times, Aira is on a mission to make the world accessible anywhere, anytime. They provide on-remand, remote visual interpretation services for the blind and low vision community. Download the app, press a button and your phone's camera streams a live video to one our highly screened Visual Interpreters.

Ebb Therapeutics

Series B in 2017
Ebb Therapeutics develops regional cerebral thermal therapy (RCTT) device for use in insomnia and sleep disorders. It offers Ebb Insomnia Therapy, a drug-free insomnia therapy. Eric Nofzinger founded Cereve in 2008 that later became Ebb Therapeutics. aIts headquarters in Pittsburgh in Pennsylvania.

ConcertoCare

Venture Round in 2016
ConcertoCare delivers primary and complex care to seniors and other adult patients. They provide three distinct in-home care models, which are all powered by their proprietary population health and analytics engine. Their novel approach to patient care is composed of their team of renowned experts in home-based geriatric medicine, digital health, palliative care, healthcare analytics, and value-based care.

nVision Medical

Series B in 2016
NVISION MEDICAL Corporation operates in the healthcare sector. The company was incorporated in 2009 and is based in Saratoga, California. nVision is a privately-held medical device company dedicated to filling the void in women’s health innovation. Since its founding in 2011, the company has relentlessly focused on developing devices to enable clinicians to assess the health of previously inaccessible parts of the female reproductive tract.

SI-BONE

Venture Round in 2016
SI-BONE provides a titanium implant fixation system for the sacroiliac joint using the patented iFuseTM implant with a cannulated delivery system. When compared to the standard SI open fusion procedure, the iFuse implant procedure is less invasive, much quicker and much simpler to achieve fixation of the sacroiliac joint.

Strata Oncology

Series A in 2016
Strata Oncology is a precision oncology company dedicated to transforming cancer care by expanding patient access to precision medicine clinical trials and accelerating drug approval. Strata's national precision oncology platform serves the needs of patients, providers and drug developers by providing a link from patient screening to streamlined enrollment in mutation-matched clinical trials. Follow us on Twitter @StrataOncology.

ArborMetrix

Series B in 2016
ArborMetrix is a performance measurement for Acute and Specialty Care. Based on its industry-changing research, ArborMetrix delivers outcomes-based, risk- and reliability-adjusted clinical intelligence, which provides actionable insights for Hospitals, Health Plans, ACOs, Physicians, Societies, and Collaboratives. Their leading healthcare analytics solutions are proven to deliver targeted, clinically-deep insights that improve clinical outcomes, optimize financial performance, increase stakeholder value, and measure the real-world effectiveness of treatments and procedures, as well as medical device technologies and pharmaceuticals. It was founded in 2011 and headquartered in Ann Arbor, Michigan.

Pear Therapeutics

Series A in 2016
Pear Therapeutics is a provider of a software-based digital therapeutics platform designed to treat disease and enhance the efficacy of pharmaceuticals. The company's platform combines novel digital interventions with drugs to enhance efficacy well beyond anything that is commercially available or in clinical development, enabling clients to get better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective services for payors.

Intellicyt

Venture Round in 2015
IntelliCyt Corporation develops cell- and bead-based screening solutions using high throughput flow technology for use in drug discovery, antibody discovery, and immunology. It provides iQue Screener platform, an integrated instrument, software, and reagent system that enables high-content multiplexed analysis of cell- and bead-based samples in liquid suspension; ForeCyt software, an intuitive workflow-based environment for data visualization, instrument control, and data analysis; and MultiCyt screening kits–cell and bead-based reagents for use on iQue Screeners. The company also offers installation, training, technical support, and repair services. Its products are used in laboratories at pharmaceutical companies, biotechnology companies, and medical centers worldwide. IntelliCyt Corporation was formerly known as Sage Sciences, Inc. The company was founded in 2006 and is based in Albuquerque, New Mexico. As of June 28, 2016, IntelliCyt Corporation operates as a subsidiary of Sartorius AG.
Delphinus Medical Technologies develops, commercializes, sells, and services breast cancer screening solutions to hospitals and imaging clinics in the United States and internationally. It commercializes SoftVue, a three-dimensional and tomographic ultrasound imaging and risk assessment device that examines women's breasts for the presence of benign and/or malignant masses, assesses breast cancer risks, diagnoses breast diseases, and monitors therapy.

Cardiac Dimensions

Series A in 2015
Cardiac Dimensions, Inc. is a medical device company developing novel interventional tools for the treatment of heart failure and the related condition of mitral valve regurgitation. Our product, the Carillon® Mitral Contour System®, is a groundbreaking, non-surgical device developed to treat functional mitral valve regurgitation. Our system uses a catheter based approach to reshape the mitral valve and reduce mitral regurgitation.

My Health Direct

Venture Round in 2014
My Health Direct operates as a health services solutions company that connects hospitals, care management organizations, public agencies, and community collaboratives for the purpose of scheduling and booking healthcare appointments on behalf of individuals. It offers a Web-based solution that organizes and books open and available healthcare appointments in the community into a searchable and schedulable inventory of healthcare services. My Health Direct, Inc. was formerly known as Global Health Direct. The company was founded in 2005 and is based in Brookfield, Wisconsin.

Cardiac Dimensions

Series A in 2014
Cardiac Dimensions, Inc. is a medical device company developing novel interventional tools for the treatment of heart failure and the related condition of mitral valve regurgitation. Our product, the Carillon® Mitral Contour System®, is a groundbreaking, non-surgical device developed to treat functional mitral valve regurgitation. Our system uses a catheter based approach to reshape the mitral valve and reduce mitral regurgitation.

RethinkFirst

Series C in 2014
At RethinkFirst, we're on a mission to empower individuals and organizations to reach their potential by providing them with the behavioral health tools, solutions and support they need to build healthier, happier and more fulfilling lives. RethinkFirst was founded in 2008 with a simple goal of providing scalable autism treatment training tools and caregiver support to an underserved population in need. In 2010, we launched our first solution – a full suite of special needs and behavior management offerings to support the K-12 education industry and quickly expanded with our Employer and Provider solutions to help the entire ecosystem providing support to the autism and developmental disability community. We were excited and humbled by the overwhelming response and support from our customers and the people that they serve but also realized that the need for behavioral health support goes far beyond individuals with formal diagnosis. From teens struggling with depression or substance abuse or just learning how to cope with growing up, to adults dealing with anxiety, sleep disorders and more, we realized that so many had challenges – and that barriers of stigma, access and cost associated were preventing so many from living the healthy, happy and fulfilling lives that they aspired to. We evolved our mission to transform the behavioral health landscape and to inspire and empower all individuals with behavioral health challenges and those who support them and once again expanding our offerings to include new wellness and mental health support to support children and adults in their daily lives.. Today, we’re proud to be a team of over 350 people working to support over 2,000 customers across the world as we work together to support our communities and help every individual power reach their potential. Our job is to create the communities of support that people need to make significant progress with their health and to put the tools in the hands of ordinary people doing extraordinary things every single day. Clinicians, parents and caregivers, educators, employers and people, that work to bring out the absolute best in the lives they touch. RethinkFirst’s cloud-based enterprise software platforms and evidence-based protocols are transforming society’s understanding of behavioral health and wellness by creating communities of support and helping everyone reach their fullest potential. Whether it’s the learning goal of a student, outcome of a patient, meditation-routine of an employee, or growth-strategy of a clinic, our expert solutions bridge the behavioral health gap between need and exceed.

NeuMoDx Molecular

Series B in 2014
NeuMoDx Molecular, Inc. operates as a molecular diagnostics company. The company develops solutions for molecular diagnostic (MDx) testing in hospital and clinical reference laboratories.

Advance Medical

Series B in 2013
Advance Medical is one of the largest, physician-based telemedicine providers, offering employers and insurers the ability to provide top-quality, concierge-level medical advice and support to patients around the globe via offices in the U.S., Europe, Asia, and South America. Founded in 1999, Advance Medical has emerged as the global leader in expert medical opinions because of its programs executed exclusively by board-certified physicians – doctors who speak by phone or video consultation with every patient, no matter what the issue or concern and for as much time as necessary, to provide best-in-class medical expertise.

Adavium

Private Equity Round in 2013
Adavium Medical is a medical equipment and diagnostics company aimed at bringing commercial sophistication to a highly fragmented market. The Company was formed with the intent to commercialize the most innovative portfolio of medical device and diagnostics products in Brazil. Adavium Medical portfolio today is made up of products that we commercialize on behalf of leading international companies. Adavium Medical assembled an experienced team of more than 300 employees that ensure that its fully-integrated commercial platform operates at world-class standards. Adavium Medical have the largest customer base across premium and “long tail” customers of any medical equipment and/or diagnostics company in Brazil, with more than 2,500 customers respectively in medical equipment and diagnostics. This is exponentially more than the average distributor or multinational in the region. The company was founded in 2011 and is headquartered in Sao Paulo, Brazil.
Delphinus Medical Technologies develops, commercializes, sells, and services breast cancer screening solutions to hospitals and imaging clinics in the United States and internationally. It commercializes SoftVue, a three-dimensional and tomographic ultrasound imaging and risk assessment device that examines women's breasts for the presence of benign and/or malignant masses, assesses breast cancer risks, diagnoses breast diseases, and monitors therapy.

ArborMetrix

Series B in 2013
ArborMetrix is a performance measurement for Acute and Specialty Care. Based on its industry-changing research, ArborMetrix delivers outcomes-based, risk- and reliability-adjusted clinical intelligence, which provides actionable insights for Hospitals, Health Plans, ACOs, Physicians, Societies, and Collaboratives. Their leading healthcare analytics solutions are proven to deliver targeted, clinically-deep insights that improve clinical outcomes, optimize financial performance, increase stakeholder value, and measure the real-world effectiveness of treatments and procedures, as well as medical device technologies and pharmaceuticals. It was founded in 2011 and headquartered in Ann Arbor, Michigan.

Fidelis SeniorCare

Series A in 2013
Fidelis SeniorCare, Inc., a managed care company, develops and administers health plans for assisted living residents in Michigan, North Carolina, and Texas. The company offers Medicare advantage special needs plans to cover the health needs of seniors living in nursing homes and assisted living communities; and individuals who require specialized healthcare. Its plans cover on-site primary care team visits, part D prescription drugs, monitoring and managing prescribed medications, transportation to the hospital or physician’s office, and skilled nursing services during a covered Medicare stay; preventive care, screening, vision/dental/hearing, and podiatry services; and emergency room, ambulance, and urgent care services. The company was founded in 2004 and is based in Schaumburg, Illinois.

Intellicyt

Venture Round in 2013
IntelliCyt Corporation develops cell- and bead-based screening solutions using high throughput flow technology for use in drug discovery, antibody discovery, and immunology. It provides iQue Screener platform, an integrated instrument, software, and reagent system that enables high-content multiplexed analysis of cell- and bead-based samples in liquid suspension; ForeCyt software, an intuitive workflow-based environment for data visualization, instrument control, and data analysis; and MultiCyt screening kits–cell and bead-based reagents for use on iQue Screeners. The company also offers installation, training, technical support, and repair services. Its products are used in laboratories at pharmaceutical companies, biotechnology companies, and medical centers worldwide. IntelliCyt Corporation was formerly known as Sage Sciences, Inc. The company was founded in 2006 and is based in Albuquerque, New Mexico. As of June 28, 2016, IntelliCyt Corporation operates as a subsidiary of Sartorius AG.

Esperion

Venture Round in 2013
Esperion discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases. Esperion intends to commercialize a novel class of drugs that focuses on a new treatment approach called "HDL Therapy," which is based on the Company's understanding of high-density lipoprotein, or HDL, function.

BAROnova

Series C in 2013
BAROnova, founded in 2006 and based in Goleta, CA, is a clinical-stage medical-device company focused on developing non-surgical non-pharmacologic devices to induce weight loss.
Tangent Medical Technologies, a development stage medical device company, was founded in Ann Arbor in 2009 based on technology exclusively licensed from the University of Michigan's Medical Innovation Center. The Company's mission is to improve infusion therapy for patients and healthcare workers with its proprietary, intravenous catheters and associated products. Tangent is led by an experienced, successful management team and the original inventors of the technology. The Company expects to begin generating commercial revenues from its lead product, the NovaCath™ Closed IV Catheter System, in 2012.

Tangent Medical Technologies

Venture Round in 2012
Tangent Medical Technologies, a development stage medical device company, was founded in Ann Arbor in 2009 based on technology exclusively licensed from the University of Michigan's Medical Innovation Center. The Company's mission is to improve infusion therapy for patients and healthcare workers with its proprietary, intravenous catheters and associated products. Tangent is led by an experienced, successful management team and the original inventors of the technology. The Company expects to begin generating commercial revenues from its lead product, the NovaCath™ Closed IV Catheter System, in 2012.

Sonitus Medical

Series D in 2012
Sonitus Medical Inc., is a privately held medical device company committed to providing innovative and clinically effective hearing solutions that Otologists, ENTs, and Audiologists can use to help their patients rejoin the conversation of life. As an emerging leader in bone conduction hearing devices, Sonitus Medical currently markets the SoundBite Hearing System, the world's first non-invasive and removable hearing solution that imperceptibly transmits sound via teeth. Relying on the principle of bone conduction, this nearly invisible ITM (in-the-mouth) hearing system is a simple and non-surgical solution that is currently FDA cleared as a prosthetic device for the treatment of single sided deafness and conductive hearing loss. Intended future applications for this platform technology include indications for hearing disorders such as mixed hearing loss and tinnitus, as well as consumer and covert communications. Founded in June 2006, Sonitus Medical is headquartered in San Mateo, California.

Uptake Medical

Series C in 2012
Uptake Medical develops innovative medical technologies for the treatment of lung diseases. Its first product, InterVapor™, is the first and only approach to endoscopic lung volume reduction for people with severe emphysema that uses the body’s natural healing process without leaving any foreign materials in the lung. In clinical studies, InterVapor has demonstrated clinically meaningful improvements in breathing function, exercise capacity and quality of life.

Cervilenz

Series A in 2012
CerviLenz is a new, disposable device that measure vaginal cervical length during a speculum exam. Cervical length is a powerful predictor of preterm birth risk and influences patient management decisions. CerviLenz gives clinicians an immediate, reliable method for measuring the cervix at the point of care. CerviLenz is manufactured and distributed by Cervilenz Inc. headquartered in Chagrin Falls, Ohio.

Hicuity Health

Series D in 2011
Hicuity Health is the nation’s leading provider of high acuity telehealth services, contracted to provide care to more than 115 hospitals in 30 states on a 24 x 7 x 365 basis. Hicuity Health is a technology-enabled clinical services provider that employs cutting edge tele-technology, U.S. board-certified intensivists, multiple dedicated tele-care delivery centers, and a proven implementation and client service approach to the benefit of patients, families, providers and hospitals.
Tangent Medical Technologies, a development stage medical device company, was founded in Ann Arbor in 2009 based on technology exclusively licensed from the University of Michigan's Medical Innovation Center. The Company's mission is to improve infusion therapy for patients and healthcare workers with its proprietary, intravenous catheters and associated products. Tangent is led by an experienced, successful management team and the original inventors of the technology. The Company expects to begin generating commercial revenues from its lead product, the NovaCath™ Closed IV Catheter System, in 2012.

Cervilenz

Venture Round in 2011
CerviLenz is a new, disposable device that measure vaginal cervical length during a speculum exam. Cervical length is a powerful predictor of preterm birth risk and influences patient management decisions. CerviLenz gives clinicians an immediate, reliable method for measuring the cervix at the point of care. CerviLenz is manufactured and distributed by Cervilenz Inc. headquartered in Chagrin Falls, Ohio.

NxThera

Series B in 2011
NxThera develops medical technologies to treat a variety of endourology conditions, including BPH. The company's technology platform utilizes a simple, minimally invasive, vapor therapy designed to measurably improve urinary flow and patient quality of life. BPH afflicts more than 32 million men in the United States.

Wellfount

Series A in 2011
Wellfount is a nationally-focused institutional pharmacy that provides drug regimen reviews, packaging, distribution and charting solutions to patients that reside in long-term care facilities such as nursing homes. Through its innovative technologies, Wellfount cuts in half the number of individual touches of a drug order from physician to patient, provides just-in-time dispense at the point of patient care, and integrates the nurses documentation into a seamless patient record. By applying these innovative solutions, Wellfount delivers significant savings and improves the quality of care provided for each patient, regardless of the payer source.

My Health Direct

Series B in 2011
My Health Direct operates as a health services solutions company that connects hospitals, care management organizations, public agencies, and community collaboratives for the purpose of scheduling and booking healthcare appointments on behalf of individuals. It offers a Web-based solution that organizes and books open and available healthcare appointments in the community into a searchable and schedulable inventory of healthcare services. My Health Direct, Inc. was formerly known as Global Health Direct. The company was founded in 2005 and is based in Brookfield, Wisconsin.

PathCentral

Series B in 2010
PathCentral, an Irvine, California-based provider of a fully integrated, web-based enterprise software platform designed specifically for community pathologists. Created by a team of pathologists and industry executives, PathCentral's solution integrates all aspects of a pathology practice's business, including ordering (accessioning), barcode-based laboratory workflow management and specimen tracking, transcription, test send-outs, professional consultations, diagnosis, reporting, billing and financial analysis.

Accuri Cytometers

Series E in 2010
Accuri Cytometers was founded to address a compelling need: life scientists love the rapid cell-by-cell analysis capability of flow cytometers, but too few have a flow cytometer in their lab. The barriers for most researchers include cost of the instrument, complexity of the software, effort required for maintenance, and the large amount of bench space required for the instrument. As a result, the company is looking to develop affordable and robust cytometers.
Delphinus Medical Technologies develops, commercializes, sells, and services breast cancer screening solutions to hospitals and imaging clinics in the United States and internationally. It commercializes SoftVue, a three-dimensional and tomographic ultrasound imaging and risk assessment device that examines women's breasts for the presence of benign and/or malignant masses, assesses breast cancer risks, diagnoses breast diseases, and monitors therapy.

Uptake Medical

Series B in 2010
Uptake Medical develops innovative medical technologies for the treatment of lung diseases. Its first product, InterVapor™, is the first and only approach to endoscopic lung volume reduction for people with severe emphysema that uses the body’s natural healing process without leaving any foreign materials in the lung. In clinical studies, InterVapor has demonstrated clinically meaningful improvements in breathing function, exercise capacity and quality of life.

CardioMEMS

Venture Round in 2010
CardioMEMS is a medical device company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body. Their technology platform is designed to improve the management of severe chronic cardiovascular diseases such as heart failure and aneurysms. Their miniature wireless sensors can be implanted using minimally invasive techniques and transmit cardiac output, blood pressure and heart rate data that are critical to the management of patients.

CardioMEMS

Series F in 2009
CardioMEMS is a medical device company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body. Their technology platform is designed to improve the management of severe chronic cardiovascular diseases such as heart failure and aneurysms. Their miniature wireless sensors can be implanted using minimally invasive techniques and transmit cardiac output, blood pressure and heart rate data that are critical to the management of patients.

Accuri Cytometers

Series D in 2009
Accuri Cytometers was founded to address a compelling need: life scientists love the rapid cell-by-cell analysis capability of flow cytometers, but too few have a flow cytometer in their lab. The barriers for most researchers include cost of the instrument, complexity of the software, effort required for maintenance, and the large amount of bench space required for the instrument. As a result, the company is looking to develop affordable and robust cytometers.

Cervilenz

Series A in 2009
CerviLenz is a new, disposable device that measure vaginal cervical length during a speculum exam. Cervical length is a powerful predictor of preterm birth risk and influences patient management decisions. CerviLenz gives clinicians an immediate, reliable method for measuring the cervix at the point of care. CerviLenz is manufactured and distributed by Cervilenz Inc. headquartered in Chagrin Falls, Ohio.

BAROnova

Series B in 2008
BAROnova, founded in 2006 and based in Goleta, CA, is a clinical-stage medical-device company focused on developing non-surgical non-pharmacologic devices to induce weight loss.

HandyLab

Series D in 2008
HandyLab is a medical technology company that develops and manufactures molecular diagnostic assays and automation platforms The company’s proprietary platform reduces the time, cost, and complexity of testing while improving the quality of results. Using patented real-time microfluidic PCR technology, its products are positioned to decentralize nucleic acid testing. HandyLab was founded in 2000 and is based in Ann Arbor, Michigan. It was acquired by Becton, Dickinson and Company in 2009.

Accuri Cytometers

Series C in 2008
Accuri Cytometers was founded to address a compelling need: life scientists love the rapid cell-by-cell analysis capability of flow cytometers, but too few have a flow cytometer in their lab. The barriers for most researchers include cost of the instrument, complexity of the software, effort required for maintenance, and the large amount of bench space required for the instrument. As a result, the company is looking to develop affordable and robust cytometers.

Hicuity Health

Series B in 2008
Hicuity Health is the nation’s leading provider of high acuity telehealth services, contracted to provide care to more than 115 hospitals in 30 states on a 24 x 7 x 365 basis. Hicuity Health is a technology-enabled clinical services provider that employs cutting edge tele-technology, U.S. board-certified intensivists, multiple dedicated tele-care delivery centers, and a proven implementation and client service approach to the benefit of patients, families, providers and hospitals.

Esperion

Series A in 2008
Esperion discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases. Esperion intends to commercialize a novel class of drugs that focuses on a new treatment approach called "HDL Therapy," which is based on the Company's understanding of high-density lipoprotein, or HDL, function.

Mirabilis Medical

Series A in 2007
Mirabilis Medic is a medical device company that focuses on the treatment of uterine fibroids that is a common problem for women. Its products include a non-invasive therapeutic solution for use by gynecologists that allows them to treat pathological tissue deep inside the body without incisions, punctures, or other damage to intervening tissue. The company was founded in 2004 and is based in Bothell, Washington.

KFx Medical

Series B in 2007
KFx® Medical, develops and manufactures innovative soft tissue fixation implants for orthopedic sports medicine surgeons. Our partnerships with the world's leading orthopaedic surgeons motivates us to develop new technology and proven surgical implants, resulting in positive surgical outcomes for the patients.

Accuri Cytometers

Series B in 2007
Accuri Cytometers was founded to address a compelling need: life scientists love the rapid cell-by-cell analysis capability of flow cytometers, but too few have a flow cytometer in their lab. The barriers for most researchers include cost of the instrument, complexity of the software, effort required for maintenance, and the large amount of bench space required for the instrument. As a result, the company is looking to develop affordable and robust cytometers.

Inogen

Series D in 2007
Inogen is innovation in oxygen therapy. Our mission is to improve freedom and independence for oxygen therapy patients through innovative products and services. As a manufacturer and Accredited Homecare Provider dedicated to oxygen therapy, Inogen is ideally suited to develop products tailored to oxygen therapy users and to provide superior service to those users in their homes.

Uptake Medical

Series A in 2006
Uptake Medical develops innovative medical technologies for the treatment of lung diseases. Its first product, InterVapor™, is the first and only approach to endoscopic lung volume reduction for people with severe emphysema that uses the body’s natural healing process without leaving any foreign materials in the lung. In clinical studies, InterVapor has demonstrated clinically meaningful improvements in breathing function, exercise capacity and quality of life.

Hicuity Health

Series A in 2006
Hicuity Health is the nation’s leading provider of high acuity telehealth services, contracted to provide care to more than 115 hospitals in 30 states on a 24 x 7 x 365 basis. Hicuity Health is a technology-enabled clinical services provider that employs cutting edge tele-technology, U.S. board-certified intensivists, multiple dedicated tele-care delivery centers, and a proven implementation and client service approach to the benefit of patients, families, providers and hospitals.

BAROnova

Series A in 2006
BAROnova, founded in 2006 and based in Goleta, CA, is a clinical-stage medical-device company focused on developing non-surgical non-pharmacologic devices to induce weight loss.

KFx Medical

Series A in 2005
KFx® Medical, develops and manufactures innovative soft tissue fixation implants for orthopedic sports medicine surgeons. Our partnerships with the world's leading orthopaedic surgeons motivates us to develop new technology and proven surgical implants, resulting in positive surgical outcomes for the patients.

HealthMedia

Venture Round in 2005
Founded in 1998, by Dr. Victor Strecher, HealthMedia® has developed a methodology and technology that effectively emulates a health coaching session, without the coach. Our one-of-a-kind programs possess the scalability of web content and deliver the efficacious outcomes a health coaching program receives.

Accuri Cytometers

Series A in 2005
Accuri Cytometers was founded to address a compelling need: life scientists love the rapid cell-by-cell analysis capability of flow cytometers, but too few have a flow cytometer in their lab. The barriers for most researchers include cost of the instrument, complexity of the software, effort required for maintenance, and the large amount of bench space required for the instrument. As a result, the company is looking to develop affordable and robust cytometers.

Asterand

Series C in 2003
Asterand Bioscience is the leading global provider of high quality, well characterized human tissue and human tissue-based research solutions to drug discovery scientists. Our mission is to provide human-based solutions to accelerate the identification and validation of drug targets and enhance the selection of drug candidates with an increased likelihood of clinical success. Asterand Bioscience has a well-established human tissue heritage, having been formed in 2006 through the merger of Asterand (founded 2000), a human tissue biorepository and Pharmagene (founded 1996) a human tissue-based drug discovery company. With this background and capability in human tissue procurement, characterization and research tools, Asterand Bioscience is uniquely positioned to provide a comprehensive approach to meet the research needs of pharmaceutical, biotechnology and diagnostic companies, as well as academia. From our offices in Detroit, MI and Royston, U.K., our employees focus on providing services and products to accelerate drug discovery research from target identification through compound evaluation and drug safety.

CardioMEMS

Series B in 2003
CardioMEMS is a medical device company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body. Their technology platform is designed to improve the management of severe chronic cardiovascular diseases such as heart failure and aneurysms. Their miniature wireless sensors can be implanted using minimally invasive techniques and transmit cardiac output, blood pressure and heart rate data that are critical to the management of patients.

NeoGuide Systems

Series B in 2003
NeoGuide Systems Inc. develops robotic endoscopic technology for natural orifice transluminal endoscopic surgery. Its technology is used in colonoscopy application to provide access to abdominal and thoracic cavities. The company was founded in 2000 and is based in San Jose, California.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.